Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

"Both Wegovy and Zepbound have demonstrated clinically significant weight reduction." "For example, if a patient has fatty liver, we will choose the GLP-1 that is proven to work best for liver ...

The weight loss drug Zepbound (tirzepatide) led to 50 percent more weight loss in a 72-week trial than Wegovy (semaglutide). Participants taking Zepbound lost 50 pounds (lb) on average, compared ...

Nearly 32% of Zepbound users ultimately lost at least a quarter of their body weight, compared with just 16% of Wegovy users. In both groups, weight loss was about 6% lower in men than in women.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s Wegovy in the first head-to-head study of the rival medicines.

Zepbound sales totaled $4.9 billion worldwide last year, while Wegovy earned nearly $8.8 billion. Both drugs were recently removed from the U.S. Food and Drug Administration's shortage list.

In key secondary endpoints, Zepbound was superior across all weight reduction targets with 64.6% of participants treated with Zepbound achieving at least 15.0% weight loss compared to 40.1% on ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.